尿素衍生物的菌根细菌标:结核病药物发现中的虚拟查机会
Vinicius de Melo Milani1, Mariana Luiza Silva1, Priscila Goes Camargo1
1Laboratório de Síntese de Moléculas Medicinais (LaSMMed), Departamento de Química, Centro de Ciências Exatas, Universidade Estadual de Londrina, Londrina, Brazil.
尿素衍生物在开发新的结核病药物方面显示出前景. 本综述确定了Mycobacterium tuberculosis中的关键分子标,并强调了用于发现有效抗结核病剂的虚拟查.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 微生物学 微生物学
背景情况:
- 结核病 (TB) 是一个主要的全球卫生问题,特别是随着耐药菌株的兴起.
- 开发新的抗结核药物对于应对这一挑战至关重要.
- 尿素衍生物具有不同的化学结构和药理性质,与药物发现相关.
研究的目的:
- 探索氨酸衍生物在结核病药物发现中的潜力.
- 在Mycobacterium tuberculosis (Mtb) 中识别尿素衍生物的分子标.
- 评估虚拟查在识别新型抗结核化合物的有用性.
主要方法:
- 关于硫尿素衍生物及其在Mtb中的标的综合文献综述.
- 识别参与mtb细胞壁生物合成的酶,分支链氨基酸 (BCAA) 途径和解毒机制.
- 探索用于药物发现的虚拟查方法.
主要成果:
- 编制了MTB中尿素衍生物的潜在分子标的综合清单.
- 关键的向酶类包括在酸,丁甘油和阿拉比南生物合成中的类.
- 此外,还确定了BCAA通路和排毒系统中的目标.
结论:
- 尿素衍生物显示出作为新型抗结核病药物设计的基础的巨大潜力.
- 确定分子标对于开发针对结核病的新治疗策略至关重要.
- 虚拟查提供了一种强有力的方法,可以加速发现有效的基于硫尿素的抗结核病药物.
更多相关视频
09:57Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
Published on: December 14, 2016
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
相关概念视频
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Drug Discovery: Overview
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
